Medtronic PLC
medtronic.comMedtronic PLC (NYSE: MDT) is a medical device company that develops, manufactures, and sells implantable and interventional therapies across cardiovascular, neuromodulation, spine, surgical, and acute care markets. Revenue comes from transactional product sales to hospitals, ambulatory care centers, physicians' offices, and other healthcare providers globally. Medtronic operates through segments that include cardiac rhythm management, cardiac ablation, neuromodulation, surgical and endoscopy, and acute care and monitoring. Key products include implantable cardiac defibrillators and resynchronization devices under the Claria, Cobalt, and Crome brands, pulsed field and cryoablation catheters for arrhythmia treatment, the SynchroMed III implantable drug infusion system, the Kyphon vertebral compression fracture portfolio, and the Reveal LINQ insertable cardiac monitor. For fiscal year ended April 25, 2025, GAAP net income attributable to Medtronic was $4.662 billion on diluted EPS of $3.61. The company is incorporated in Ireland and operates worldwide, with reimbursement from government programs including Medicare, Medicaid, and volume-based procurement tenders in China affecting pricing across its product lines.
Products & Services
Cardiac rhythm devices: Claria, Amplia, Compia CRT-D/CRT-P families; Cobalt and Crome BlueSync CRT-Ds; Arctic Front Advanced Cardiac Cryoablation System; PulseSelect Pulsed Field Ablation catheter; Sphere-9 focal catheter; Affera Mapping and Navigation System with Prism-1 software; Reveal LINQ and LINQ II insertable cardiac monitors. Neuromodulation: SynchroMed III Implantable Infusion System. Spine and interventional: Kyphon Kyphoplasty and Vertebroplasty portfolio; OsteoCool cooled radiofrequency ablation system; Emprint Microwave with Thermosphere technology; Accurian nerve ablation system. Medical Surgical Portfolio covering Surgical and Endoscopy and Acute Care and Monitoring divisions.
Revenue Model
Transactional product sales of implantable devices, capital equipment, disposables, and consumables to hospitals, ambulatory care centers, and physicians. Reimbursement levels set by Medicare, Medicaid, private insurers, and national tender programs in markets including China directly influence realized selling prices.
Customers & Markets
Primary customers are hospitals and healthcare systems, physicians' offices, ambulatory care centers, and alternate-site healthcare providers. End markets include cardiac arrhythmia management, heart failure, chronic and cancer pain, spasticity, vertebral compression fractures, metastatic bone lesions, liver tumors, and general surgical and acute care settings. Government payers including Medicare and Medicaid, private insurers, and managed-care plans are the indirect economic buyers that set reimbursement rates.
Geographic Exposure
Worldwide operations subject to laws and regulations across multiple jurisdictions. Specific revenue by geography is not detailed in the provided filing excerpts. The filing references the U.S., China (volume-based procurement tenders), and other international markets as material operating geographies.
Peers: STERIS plc Trinity Biotech PLC
Source: SEC 10-K, filed 2025-06-20
Loading...
